Why Ocular Therapeutix Was Bumping Higher This Week
The market was seeing Ocular Therapeutix (NASDAQ: OCUL) very positively this week, and that sunny view pushed the company's stock higher.As of Friday morning before market open, the eye care specialist's shares were up by nearly 5% in price week to date, according to data compiled by S&P Global Market Intelligence. A key catalyst for this was an analyst's bullish initiation of coverage on the biotech's stock. Early Tuesday morning, Needham's Serge Belanger formally became an Ocular analyst. He inaugurated his run by tagging the company's stock as a buy at a price target of $15 per share. That's nearly double the stock's current level. Continue reading
The market was seeing Ocular Therapeutix (NASDAQ: OCUL) very positively this week, and that sunny view pushed the company's stock higher.
As of Friday morning before market open, the eye care specialist's shares were up by nearly 5% in price week to date, according to data compiled by S&P Global Market Intelligence. A key catalyst for this was an analyst's bullish initiation of coverage on the biotech's stock.
Early Tuesday morning, Needham's Serge Belanger formally became an Ocular analyst. He inaugurated his run by tagging the company's stock as a buy at a price target of $15 per share. That's nearly double the stock's current level.
